1 research outputs found
Acetylcholinesterase and Aβ Aggregation Inhibition by Heterometallic Ruthenium(II)–Platinum(II) Polypyridyl Complexes
Two
heteronuclear rutheniumÂ(II)–platinumÂ(II) complexes [RuÂ(bpy)<sub>2</sub>(BPIMBp)ÂPtCl<sub>2</sub>]<sup>2+</sup> (<b>3</b>) and
[RuÂ(phen)<sub>2</sub>(BPIMBp)ÂPtCl<sub>2</sub>]<sup>2+</sup> (<b>4</b>), where bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline,
and BPIMBp = 1,4′-bisÂ[(2-pyridin-2-yl)-1H-imidazol-1-ylmethyl]-1,1′-biphenyl,
have been designed and synthesized from their mononuclear precursors
[RuÂ(bpy)<sub>2</sub>(BPIMBp)]<sup>2+</sup> (<b>1)</b> and [RuÂ(phen)<sub>2</sub>(BPIMBp)]<sup>2+</sup> (<b>2</b>) as multitarget molecules
for Alzheimer’s disease (AD). The inclusion of the cis-PtCl<sub>2</sub> moiety facilitates the covalent interaction of RuÂ(II) polypyridyl
complexes with amyloid β (Aβ) peptide. These multifunctional
complexes act as inhibitors of acetylcholinesterase (AChE), Aβ
aggregation, and Cu-induced oxidative stress and protect neuronal
cells against Aβ-toxicity. The study highlights the design of
metal based anti-Alzheimer’s disease (AD) systems